As of 2025-07-03, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -2.17 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.85 CAD, the upside of Cardiol Therapeutics Inc is -217.08%.
Based on its market price of 1.85 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 217.08%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.17 - -2.17 | -2.17 | -217.08% |
| P/E | (3.27) - (4.63) | (3.97) | -314.8% |
| DDM - Stable | (4.17) - (13.86) | (9.02) | -587.3% |
| DDM - Multi | (0.07) - (0.17) | (0.10) | -105.2% |
| Market Cap (mil) | 152.83 |
| Beta | 2.70 |
| Outstanding shares (mil) | 82.61 |
| Enterprise Value (mil) | 129.69 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.04% |
| Cost of Debt | 5.00% |
| WACC | 9.04% |